Rafat Abonour

United States

Professor at IU Health

myeloma doctor

Featured in: Favicon

wiley.com

dovepress.com Favicon

onclive.com Favicon

onlinelibrary.wiley.com

Articles

High‐dose chemotherapy and peripheral blood stem cell transplantation as salvage therapy in primary mediastinal nonseminomatous germ cell tumors: The Indiana University experience

May 21, 2024 | acsjournals.onlinelibrary.wiley.com | Noah Richardson |Fadi Taza |Rafat Abonour |Sandra K. Althouse

INTRODUCTION Primary extragonadal germ cell tumors comprise only 5% of germ cell tumors and arise most commonly in the mediastinum in adults.1 Primary mediastinal nonseminomatous germ cell tumors (PMNSGCTs), although similar in histology and cytogenetics to testicular germ cell tumors, have less response to cisplatin-based chemotherapy and are classified as poor-risk disease regardless of other factors, such as the size of the tumor, amplitude of serum tumor markers (STMs), and other factors...
Treatment Considerations and Sequencing in Multiple Myeloma

Feb 19, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour

The expert panel concludes their discussion with clinical insights on treatment sequencing and therapeutic decision-making for patients who have relapsed.
CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment Landscape

Feb 19, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour

CAR T-Cell Therapy in Multiple Myeloma: Role in the Treatment LandscapeA roundtable discussion on the evolving treatment landscape surrounding CAR T-cell therapy in multiple myeloma, with a focus on future directions and the management of adverse events.
GPRC5D-Targeting Bispecifics in Multiple Myeloma

Feb 12, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour

The expert panel discusses recent clinical trial data on GPRC5D-targeting bispecific antibodies and how they apply to the multiple myeloma treatment paradigms.
Adverse Effects Related to Bispecifics in Multiple Myeloma

Feb 12, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour

Comprehensive insights on the adverse effects seen from bispecific antibodies in the treatment of patients with multiple myeloma.
Real-World Evidence and Selecting Optimal Bispecifics in Multiple Myeloma

Feb 5, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour

Dr Levy on Unanswered Questions Regarding the Mechanism of Action of ADCs in NSCLC
BCMA-Targeted CAR-T Therapies in Development and Future Perspective

Jan 30, 2024 | onclive.com | Rafat Abonour |Noopur Raje

Dr. Raje and Dr. Abonour provide an insightful reflections on unmet needs and future perspectives in Relapsed/Refractory Multiple Myeloma (R/R MM), offering a glimpse into the evolving landscape of myeloma care.
Optimizing BCMA-Targeted CAR-T Therapies: Patient Selection, Clinical Impact, and Treatment Sequencing

Jan 30, 2024 | onclive.com | Rafat Abonour |Noopur Raje

Experts delve into the optimal positioning of BCMA-targeted CAR-T therapies in the treatment plan for Relapsed/Refractory Multiple Myeloma (R/R MM), providing valuable perspectives on strategic considerations in myeloma care.
Updates on BCMA-Targeting Bispecifics in MM

Jan 29, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour
Potential Role for CAR T-Cell Therapy in MM at Early Relapse

Jan 29, 2024 | onclive.com | Amrita Krishnan |Saad Usmani |Rafat Abonour

Potential Role for CAR T-Cell Therapy in MM at Early RelapseKrina Patel, MD, reviews data from the CARTITUDE-4 and KarMMa-3 studies and shares perspectives on a potential role for CAR T-cell therapy at early relapse.